Jens Rueter

Chief Medical Officer at The Jackson Laboratory, Medical Director for the Maine Cancer Genomics Initiative, community oncologist in rural Maine

[Jens Rueter @RueterJens]

@nirav_maine @HHSGov @BARDA And 8) while not as far along and as straightforward, mRNA vaccine could also be helpful in other diseases like cancer!

[Jens Rueter @RueterJens]

Great honor to have @Dr_R_Kurzrock, a true pioneer in Precision Oncology, at our 2024 MCGI Forum. @jax_mcgi @JAXcancercenter @jacksonlab

[Razelle Kurzrock, MD @Dr_R_Kurzrock]

Honor to give the Keynote for the MCGI Forum, and to meet Jens Reuter, the CMO for The Jackson Laboratory
Amazing meeting and dinner too!!

[Razelle Kurzrock, MD @Dr_R_Kurzrock]

Honor to give the Keynote for the MCGI Forum, and to meet Jens Reuter, the CMO for The Jackson Laboratory
Amazing meeting and dinner too!!

[SWOG Cancer Research Network @SWOG]

Congratulations @MeghnaTrivedi3 @RueterJens @Amich1122 @DrDawnHershman et al for their Featured Abstract @ #ASCOQLTY23: "Mixed-methods analysis of physician genomic confidence in ... cluster randomized trial evaluating genomic tumor boards (@SWOG S2108CD)" https://t.co/m4IqQvKyLR

[Vivek Subbiah, MD @VivekSubbiah]

🚨🚨Exciting news! Hot off the press with a simultaneous publication in @AACR Cancer Discovery @CD_AACR with the @ASCO #ASCO23 clinical science symposium meeting 👉🏼 So honored to present to the world 👉🏼RLY-4008 - the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations & resistance mutations.
🔺Promising results in FGFR2-positive cholangiocarcinoma & other advanced solid tumors @OncoAlert @ElizSMcKenna @AliSchram @OncBrothers #PrecisionMedicine for the win 🎯🧬
https://t.co/pkyxqsMoCz

[Jens Rueter @RueterJens]

Fascinating data

[Ben Westphalen @BenWestphalen]

Now live at #ASCO23 @kanwal_raghav presenting DESTINY-CRC02 of TDX in heavily pretreated met HER2✅ #crcsm 💙

ORR: 37.8%
DoR: 8.1 months
PFS: 5.8 months

At 5.4 mg/kg

#PrecisionMedicine @OncoAlert 🚨

[Jens Rueter @RueterJens]

Universal germline testing in all cancer patients would certainly change current practice. While thought-provoking and intriguing, this will also require novel approaches in care delivery, including education of clinicians and patients. @jax_mcgi @JAXClinicalEd @JAXcancercenter

[Ed Esplin, MD, PhD @EdEsplin]

UPDATE:
#Germlinetesting is standard of care for #breastcancer, #coloncancer, #ovariancancer, #prostatecancer, & #PancreaticCancer

#Universal #germlinetesting needed to win the war against #cancer @Vi@VivekSubbiah @Dr_R_Kurzrock @JCO_ASCO https://t.co/Tn0sGbYq8H

"We are going to be incorporating #germlinetesting in most if not all of our #patients w/ #cancer...& we've got to be prepared for that" - #DrRenatoMartins @VCUMassey @ASCO #ASCO23

#access #reducedisparities #genetictesting #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention

[Roel Verhaak @roelverhaak]

Finally, some good news for patients with IDH mutant glioma!! Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/OW5nbNAfCL

[Jens Rueter @RueterJens]

When not at ⁦@ASCO⁩ 2023…not so bad reading about the presentations in front of a nice wood stove fire on this uncharacteristically cool June day in Maine…

[Jens Rueter @RueterJens]

Such an important study. @SWOG 1826…

[Jonathan Friedberg @DrJFriedberg]

Today is the day! @SWOG 1826 data will be presented at @ASCO plenary, with discussion from @DrLaCasce

https://t.co/ZnA7gu64iW

[Jens Rueter @RueterJens]

Precision oncology, one step at a time…@SWOG

[SWOG Cancer Research Network @SWOG]

Dr. @NaglaAKarimMD presents results of @SWOG S1929 at #ASCO23:
Adding a PARP inhibitor (talazoparib) to checkpoint blockade significantly extended PFS for patients w extensive-stage small-cell #lungcancer whose tumors express SLFN11. Biomarker selected treatment in #SCLC #LCSM

[Jens Rueter @RueterJens]

Another important finding supporting rational drug choices. @jax_mcgi

[JCO Precision Oncology @JCOPO_ASCO]

.@KariWisinski_MD et al report on results from #NCI-MATCH trial where trametinib didn't meet its objective response rate goal in NF1, GNAQ or GNA11 altered tumors but some stable diseases observed suggest need to explore further in certain disease types: https://t.co/4PVsgT7icc

[Laura Esfeller @LauraEsfeller]

REALLY excited for this @SWOG S2108CD trial using #genomictumortesting to inform treatment options for any solid tumor #cancerpatients w/ #metastatic or #recurrentdisease. Find out more below! #CancerTwitter #OncTwitter #swogonc #clinicalstudies

https://t.co/BJ79vdQLga

[Jens Rueter @RueterJens]

@LauraEsfeller @SWOG Thanks for your support for our study!

[Jens Rueter @RueterJens]

On the heels of this publication, it’s great to be at the Spring 2023 @SWOG meeting and run into @ARosen380 and listen to @MeghnaTrivedi3’s great talk at the Translational Medicine Plenary, mentioning our S2108CD cluster-randomized trial investigating genomic tumor boards

[Jens Rueter @RueterJens]

Very happy to share our experience in implementing a rural community precision oncology program in Maine. #PrecisionMedicine @jacksonlab @jax_mcgi @JAXClinicalEd @JAX_CKB @NorthernLightH @MaineHealth https://t.co/f51ZuKsFAF

[Jens Rueter @RueterJens]

Very happy to share our experience in implementing a rural community precision oncology program in Maine. #PrecisionMedicine @jacksonlab @jax_mcgi @JAXClinicalEd @JAX_CKB @NorthernLightH @MaineHealth https://t.co/f51ZuKsFAF

[Jens Rueter @RueterJens]

This is the future.

[Richard Schilsky @rschilsky]

Thanks Winette and @EORTC for organizing a terrific workshop on pragmatic trials!

[JAX Genomic Education @JAX_Education]

Biomedical researchers and clinical experts are giving guest lectures about cancer biology, the unique features of cancer genomes, bioinformatic approaches used in #CancerResearch and more.

Yesterday, Dr. Jens Rueter (@RueterJens) discussed human subjects research and @JAX_MCGI!

[Jens Rueter @RueterJens]

Congrats to @ProfDMThomas and team. Important findings regarding the attitudes of cancer patients towards their own genetic and genomic findings

[Professor DM Thomas @ProfDMThomas]

94% of individuals affected by cancer want to know genetic results which are preventable or treatable. 60% want to know, even if there are no treatments. @OmicoAustralia @UNSWMedicine #RisC study. https://t.co/kAvhahdOoo

[SWOG Cancer Research Network @SWOG]

.@HemOncToday interviews @MeghnaTrivedi3 and @RueterJens on @SWOG S2108CD #clinicaltrial:
Trial to investigate impact of genomic tumor board on physician, patient outcomes https://t.co/YKzqUSGdZi